Genotypic and phenotypic testing prior to initiation in treatment-experienced patients.
Monitor viral load prior to initiation or modification of ARV treatment at 2-8 weeks.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.